Assessing the added value of apparent diffusion coefficient, cerebral blood volume, and radiomic magnetic resonance features for differentiation of pseudoprogression versus true tumor progression in patients with glioblastoma.
Riccardo LeoneHagen MeredigMartha Foltyn-DumitruFelix SahmStefan HamelmannFelix KurzTobias KesslerDavid BonekampHeinz-Peter SchlemmerMikkel Bo HansenWolfgang WickMartin BendszusPhilipp VollmuthGianluca BrugnaraPublished in: Neuro-oncology advances (2023)
Currently available imaging biomarkers could not reliably differentiate PsPD from true tumor progression in patients with glioblastoma; larger collaborative efforts are needed to build more reliable models.